Fumarate Hydratase-Deficient Leiomyomas: A Retrospective Case Series with Clinical and Familial Findings Suggestive of Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome

In: Gynecology Obstetrics & Reproductive Medicine · 2026 · pp. 1–7 · doi:10.21613/gorm.2025.1668 · W7159868941
article OA: diamond CC0

Abstract

OBJECTIVES: Fumarate hydratase (FH)-deficient uterine leiomyomas are a rare variant of smooth muscle tumors that may signal underlying hereditary syndromes like HLRCC, making their recognition crucial for gynecologists and pathologists. STUDY DESIGN: This retrospective case series included ten patients who underwent surgery for uterine fibroids (benign smooth muscle tumors) between November 2015 and October 2023. Immunohistochemistry (IHC)-a lab technique using antibodies to detect specific proteins in tissue-was performed to confirm fumarate hydratase (FH) deficiency. After confirmation, patients underwent renal ultrasonography (kidney ultrasound) and had available imaging reviewed (CT and MRI, both advanced modalities). Each patient also underwent skin assessment for cutaneous leiomyomas (skin tumors) and received counseling for FH deficiency. Demographic, clinical, surgical, and familial data were collected and analyzed descriptively. RESULTS: The mean age of patients was 40.2 years (range: 27-52), and the mean BMI was 26.9 ± 3.8 kg/m². Five patients underwent myomectomy, including one laparoscopically. The remaining five had a hysterectomy via Pfannenstiel incision. All diagnoses of FH-deficient leiomyomas were confirmed by immunohistochemistry. Two patients exhibited notable co-pathologies: one with adenomyosis and the other with a low-grade appendiceal mucinous neoplasm (LAMN). Family history findings included one patient with a sibling diagnosed with renal cell carcinoma, one patient with a sibling diagnosed with endometrial cancer, and another patient with first-degree relatives affected by uterine leiomyoma and endometrial intraepithelial neoplasia. Germline FH mutation analysis was not performed for any patient. Fertility-preserving procedures were offered to women of reproductive age, but no pregnancies were recorded during follow-up. CONCLUSION: FH-deficient leiomyomas (fibroids lacking fumarate hydratase activity) should be considered in patients with large, multiple, or early-onset fibroids. Histopathology (examination of tissue under a microscope) and IHC (immunohistochemistry, a specialized lab technique for identifying proteins in tissue) are essential for diagnosis. Germline FH testing (testing for inherited mutations in the FH gene) was not systematically performed in our cohort. However, genetic referral (to a genetics specialist) was offered to 5 patients in the most recent year. This reflects a shift toward integrating molecular assessment into clinical practice. Our experience highlights the need to incorporate genetic counseling, routine renal imaging (regular kidney scans), and dermatologic evaluation (skin checks) into follow-up, especially for patients with features suggestive of a syndromic condition (that is, symptoms that could indicate a genetic syndrome).
Full text 3,839 characters · extracted from oa-html · 3 sections · click to expand

Objectives

Fumarate hydratase (FH)-deficient uterine leiomyomas are a rare variant of smooth muscle tumors that may signal underlying hereditary syndromes like HLRCC, making their recognition crucial for gynecologists and pathologists. STUDY DESIGN: This retrospective case series included ten patients who underwent surgery for uterine fibroids (benign smooth muscle tumors) between November 2015 and October 2023. Immunohistochemistry (IHC)-a lab technique using antibodies to detect specific proteins in tissue-was performed to confirm fumarate hydratase (FH) deficiency. After confirmation, patients underwent renal ultrasonography (kidney ultrasound) and had available imaging reviewed (CT and MRI, both advanced modalities). Each patient also underwent skin assessment for cutaneous leiomyomas (skin tumors) and received counseling for FH deficiency. Demographic, clinical, surgical, and familial data were collected and analyzed descriptively.

Results

The mean age of patients was 40.2 years (range: 27-52), and the mean BMI was 26.9 ± 3.8 kg/m². Five patients underwent myomectomy, including one laparoscopically. The remaining five had a hysterectomy via Pfannenstiel incision. All diagnoses of FH-deficient leiomyomas were confirmed by immunohistochemistry. Two patients exhibited notable co-pathologies: one with adenomyosis and the other with a low-grade appendiceal mucinous neoplasm (LAMN). Family history findings included one patient with a sibling diagnosed with renal cell carcinoma, one patient with a sibling diagnosed with endometrial cancer, and another patient with first-degree relatives affected by uterine leiomyoma and endometrial intraepithelial neoplasia. Germline FH mutation analysis was not performed for any patient. Fertility-preserving procedures were offered to women of reproductive age, but no pregnancies were recorded during follow-up.

Conclusion

FH-deficient leiomyomas (fibroids lacking fumarate hydratase activity) should be considered in patients with large, multiple, or early-onset fibroids. Histopathology (examination of tissue under a microscope) and IHC (immunohistochemistry, a specialized lab technique for identifying proteins in tissue) are essential for diagnosis. Germline FH testing (testing for inherited mutations in the FH gene) was not systematically performed in our cohort. However, genetic referral (to a genetics specialist) was offered to 5 patients in the most recent year. This reflects a shift toward integrating molecular assessment into clinical practice. Our experience highlights the need to incorporate genetic counseling, routine renal imaging (regular kidney scans), and dermatologic evaluation (skin checks) into follow-up, especially for patients with features suggestive of a syndromic condition (that is, symptoms that could indicate a genetic syndrome). Downloads Downloads Published How to Cite Issue Section License Copyright (c) 2026 Tural Ismayilov, Suleyman Cemil Oglak, Nebahat Uzunay, Zeynep Yavas Yucel This work is licensed under a Creative Commons Attribution 4.0 International License. All the articles published in GORM are licensed with "Creative Commons Attribution 4.0 License (CC BY 4.0)". This license entitles all parties to copy, share and redistribute all the articles, data sets, figures and supplementary files published in this journal in data mining, search engines, web sites, blogs and other digital platforms under the condition of providing references.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-07-30T06:08:59.260406+00:00
License: CC0 · commercial use OK